PANCREAZE

Indicated For

Exocrine Pancreatic Insufficiency (EPI)

About This Medication

# PANCREAZE Patient Assistance Program Guide: How to Get PANCREAZE at Low or No Cost PANCREAZE (pancrelipase) is a prescription medication used to treat **exocrine pancreatic insufficiency (EPI)**, a condition where your pancreas doesn't produce enough digestive enzymes to break down food properly. The **PANCREAZE Patient Assistance Program (PAP)** from manufacturer **VIVUS** helps eligible patients get this important therapy at low or no cost if you meet specific financial and insurance criteria. ## About PANCREAZE and Why You Might Need It PANCREAZE is a **pancreatic enzyme replacement therapy (PERT)** made from porcine-derived enzymes—lipases, proteases, and amylases—that help digest fats, proteins, and carbohydrates. It's taken with meals and snacks to manage symptoms of EPI, such as diarrhea, weight loss, gas, and malnutrition. EPI can result from conditions like cystic fibrosis, chronic pancreatitis, pancreatic surgery, or pancreatic cancer. If you're struggling with these symptoms or have been prescribed PANCREAZE but can't afford it, this program may provide free medication shipped directly to your home. **Important:** Always follow your doctor's instructions on dosing, which is typically based on your weight, meal size, and fat content. Do not crush or chew the delayed-release capsules unless directed. ## Who Qualifies for the Program? The PANCREAZE PAP is designed for **uninsured or underinsured patients** facing financial hardship. While exact income thresholds like Federal Poverty Level (FPL) percentages aren't publicly specified, the program considers **specific financial criteria**. A key eligibility note: **Medicare Part D patients** may qualify if they spend **4% or more of their gross annual income** on prescriptions. You must also agree **not to seek reimbursement** from any third-party payer (like Medicaid, Medicare, or private insurance) for the medication provided. This is a free medication program, separate from VIVUS's copay assistance (which helps commercially insured patients pay as little as $0 per fill, up to $2,000 per fill and $3,500 annually).[1] ### Income Eligibility Breakdown | Household Size | Income Threshold | Notes | |---------------|------------------|-------| | Individual | Not specified | Based on specific financial criteria; contact program for details. | | Couple | Not specified | Same as above. | | Family of 3 | Not specified | Same as above. | | Family of 4+ | Not specified | Same as above. | **FPL Percent:** Not specified. **Pro Tip:** Call (855) 751-5540 to discuss your situation—they'll review your finances confidentially. Programs like this often align with 400-500% FPL, but verification is required. ## Insurance Requirements - **No third-party billing:** You cannot file claims for reimbursement with Medicaid, Medicare (except limited Part D cases), or private insurance for PANCREAZE received through the PAP. - **Medicare Part D:** Eligible if prescription costs exceed 4% of gross annual income. - **Commercially Insured:** Consider VIVUS's copay card instead (visit www.pancreaze.com for details), as PAP is primarily for those without coverage.[1] - **Uninsured:** Ideal candidates. If you have insurance but high out-of-pocket costs, ask your doctor about prior authorizations or switching to the copay program. ## Step-by-Step Application Process The program offers **multiple application methods** for convenience. Here's how to apply: 1. **Gather Documents:** You'll need a **completed patient section with your signature** and a **healthcare professional (HCP) completed section with their signature**. No additional proofs like pay stubs are listed, but have income details ready. 2. **Download the Form:** Visit [https://pancreazepap.com/pancreaze/pdf](https://pancreazepap.com/pancreaze/pdf) to get the application PDF. 3. **Fill It Out:** Complete your section (personal info, income, insurance status). Have your doctor or prescriber fill theirs (medical necessity, dosage). 4. **Submit:** Options include: - **Phone:** Call (855) 751-5540 for guidance or verbal start. - **Mail/Fax:** Follow instructions on the form. - **Online Portal:** Check the website for digital upload. 5. **Wait for Approval:** Processing time varies (not specified—expect 2-4 weeks based on similar programs). You'll get notification by mail or phone. 6. **Receive Medication:** If approved, PANCREAZE is **shipped free to your home**. **Reauthorization is required** annually or when your supply ends—your doctor must resubmit. **Tips for Success:** Apply early, ensure signatures are clear, and confirm your address. Involve your doctor's office early—they handle most paperwork. ## Timeline and Delivery - **Approval:** Typically 2-4 weeks, though not officially stated. Follow up via phone if delayed. - **Delivery:** Shipped directly to you at no cost. Expect standard ground shipping (5-10 business days post-approval). - **Supply Duration:** Often 1-3 months per approval; reapply before running out. - **Refills:** **Reauthorization required**—plan ahead with your HCP. ## What If You're Denied or Need Alternatives? - **Denied?** Common reasons: income too high, insurance conflict, incomplete forms. Call (855) 751-5540 to appeal or clarify. Explore state assistance, generic PERTs (like Creon alternatives if available), or patient foundations like PanCAN. - **No Biosimilars:** No listed alternatives in the program. - **Other Options:** - VIVUS Copay Card for insured patients.[1] - NeedyMeds.org or RxAssist.org for EPI resources. - Doctor samples or hospital charity care. ## Disclaimer This guide is for informational purposes only and based on publicly available program details as of 2026. Eligibility, terms, and availability can change—**always verify directly with VIVUS at (855) 751-5540 or pancreazepap.com**. Not medical advice; consult your healthcare provider for treatment decisions. VIVUS reserves the right to modify or end the program. PANCREAZE has risks (e.g., fibrosing colonopathy with high doses)—discuss with your doctor.

Program information last verified: March 30, 2026